AQR Capital Management
MLTX icon

AQR Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

AQR Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$861K Buy
46,185
+13,299
+40% +$220K ﹤0.01% 2853
2025
Q4 		$433K Buy
+32,886
New +$388K ﹤0.01% 2987
2024
Q2 		– Sell
-5,858
Closed -$294K – 2647
2024
Q1 		$294K Sell
5,858
-630
-10% -$34.2K ﹤0.01% 2136
2023
Q4 		$392K Buy
+6,488
New +$334K ﹤0.01% 1977

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management's MLTX Position: Q1 2026 in Review

AQR Capital Management increased its MoonLake Immunotherapeutics (MLTX) stake by 40% in Q1 2026, buying an estimated $220K and bringing the position to 46,185 shares worth $861K. The position accounts for ﹤0.01% of the portfolio, ranked #2853.

AQR Capital Management first reported a position in MLTX in Q4 2023 and has held it in 4 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • AQR Capital Management held 46,185 shares of MoonLake Immunotherapeutics worth $861K as of Q1 2026.
  • AQR Capital Management bought 13,299 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $220K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2853 holding.
  • AQR Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 4 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.